MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/57.5/0.1/20.12.24 | Market Closed - Börse Stuttgart 02:28:03 2024-07-05 pm EDT | ||
| 1.97 EUR | +1.55% |
|
| Current month | -5.74% | ||
| 1 month | -14.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 1.97 | +1.55% |
| 24-07-04 | 1.94 | +0.52% |
| 24-07-03 | 1.93 | -2.53% |
| 24-07-02 | 1.98 | -2.46% |
| 24-07-01 | 2.03 | -2.87% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 02:28 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3F1W |
| ISIN | DE000MB3F1W1 |
| Date issued | 2023-02-08 |
| Strike | 57.5 $ |
| Maturity | 2024-12-20 (168 Days) |
| Parity | 10 : 1 |
| Emission price | 1.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.31 € |
|---|---|
| Lowest since issue | 0.71 € |
| Spread | 0.02 € |
| Spread % | 1.00% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
154.4
USD
Average target price
174.6
USD
Spread / Average Target
+13.10%
- Stock Market
- Warrants
- Warrant
